GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (FRA:ONMA) » Definitions » ROE %

OncoSec Medical (FRA:ONMA) ROE % : 0.00% (As of Jan. 2023)


View and export this data going back to 2015. Start your Free Trial

What is OncoSec Medical ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. OncoSec Medical's annualized net income for the quarter that ended in Jan. 2023 was €-25.47 Mil. OncoSec Medical's average Total Stockholders Equity over the quarter that ended in Jan. 2023 was €-3.05 Mil. Therefore, OncoSec Medical's annualized ROE % for the quarter that ended in Jan. 2023 was N/A%.

The historical rank and industry rank for OncoSec Medical's ROE % or its related term are showing as below:

FRA:ONMA's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -42.76
* Ranked among companies with meaningful ROE % only.

OncoSec Medical ROE % Historical Data

The historical data trend for OncoSec Medical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical ROE % Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -231.87 -130.84 -218.00 -172.60 -175.79

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -165.55 -152.35 -342.29 -1,305.20 -

Competitive Comparison of OncoSec Medical's ROE %

For the Biotechnology subindustry, OncoSec Medical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSec Medical's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's ROE % distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's ROE % falls into.



OncoSec Medical ROE % Calculation

OncoSec Medical's annualized ROE % for the fiscal year that ended in Jul. 2022 is calculated as

ROE %=Net Income (A: Jul. 2022 )/( (Total Stockholders Equity (A: Jul. 2021 )+Total Stockholders Equity (A: Jul. 2022 ))/ count )
=-33.599/( (32.212+6.014)/ 2 )
=-33.599/19.113
=-175.79 %

OncoSec Medical's annualized ROE % for the quarter that ended in Jan. 2023 is calculated as

ROE %=Net Income (Q: Jan. 2023 )/( (Total Stockholders Equity (Q: Oct. 2022 )+Total Stockholders Equity (Q: Jan. 2023 ))/ count )
=-25.468/( (-0.999+-5.091)/ 2 )
=-25.468/-3.045
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jan. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


OncoSec Medical  (FRA:ONMA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jan. 2023 )
=Net Income/Total Stockholders Equity
=-25.468/-3.045
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-25.468 / 0)*(0 / 11.444)*(11.444 / -3.045)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*N/A
=ROA %*Equity Multiplier
=N/A %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jan. 2023 )
=Net Income/Total Stockholders Equity
=-25.468/-3.045
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-25.468 / -25.456) * (-25.456 / -28.448) * (-28.448 / 0) * (0 / 11.444) * (11.444 / -3.045)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0005 * 0.8948 * N/A % * 0 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Jan. 2023) net income data. The Revenue data used here is four times the quarterly (Jan. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


OncoSec Medical ROE % Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSec Medical Business Description

Traded in Other Exchanges
N/A
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

OncoSec Medical Headlines

No Headlines